Clinical observation of caffeic acid for the treatment of leukopenia and thrombocytopenia induced by imatinib in patients with chronic myeloid leukemia
10.3760/cma.j.issn.1009-9921.2013.02.013
- VernacularTitle:咖啡酸治疗伊马替尼致慢性粒细胞白血病患者血小板、白细胞减少的临床观察
- Author:
Silin GAN
;
Jianwen ZHOU
;
Hui SUN
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Caffeic acid;
Thrombocytopenia;
Leukopenia;
Imatinib
- From:
Journal of Leukemia & Lymphoma
2013;22(2):105-106
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the curative effect and adverse reaction of caffeic acid (CFA) for leukopenia and thrombocytopenia caused by imatinib in chronic myeloid leukemia (CML) patients.Methods The effect and adverse reactions of CFA for leukopenia or thrombocytopenia induced by imatinib in 42 CML patients were observed.The CFA was admitted by 0.2 g/time,3 times/d,oral.Results 21 cases of 42 CML patients with thrombocytopenia achieved remarkable curative effect after CFA treatment,13 achieved good effect and 8 had no effect.The total effective rate was 81.0 ％ (34/42).While 15 of 28 leukopenia CML patients achieved remarkable curative effect,8 achieved good effect and 5 had no effect.The total effective rate was 82.1％ (23/28).After CFA therapy for 2 weeks,both platelet and white blood cells count were elevated compared with before treatment,the differences were statistically significant (t =2.015,P =0.023,t =1.913,P =0.035).The average onset time of CFA for leukopenia and thrombocytopenia was 2 weeks and no treatment-related adverse reaction was found.Conclusion CFA is an effective and safe auxiliary drug for treatment of imatinib-induce leukopenia and thrombocytopenia in patients with CML.
